Celgene gets refusal to file letter for ozanimod

Celgene Corp. (NASDAQ:CELG) said FDA issued a refusal to file letter for an NDA for multiple sclerosis therapy ozanimod (RPC1063), which could be a key near-term

Read the full 263 word article

User Sign In